Evidence map›Paper›PMID 23747773›Full record

ArticleJournal of the American College of Cardiology2013

Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion.

Jeffrey M Testani, Meredith A Brisco, Jennifer Chen, Brian D McCauley, Chirag R Parikh, W H Wilson Tang

Abstract read
In one paragraph

Article in Journal of the American College of Cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jeffrey M TestaniDepartment of Internal Medicine and Program of Applied Translational Research, Yale University School of Medicine, New Haven, CT 06510, USA. jeffrey.testani@yale.edu
Meredith A Brisco
Jennifer Chen
Brian D McCauley
Chirag R Parikh
W H Wilson Tang

Funding

Cardiology & pulmonary research training grantT32HL007891 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Jason D Christie · 1998 to 2026
$12.0M
Training Program in Cardiovascular Biology and MedicineT32HL007843 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI THOMAS P. CAPPOLA, Sharlene M Day · 1996 to 2026
$11.0M
Mentoring Program for Translational and Patient Oriented Research in AKIK24DK090203 · NIDDK · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2012 to 2016
$896k
Cardio-renal phenotype and prognosis in chronic heart failureK23HL114868 · NHLBI · YALE UNIVERSITY · PI TESTANI, JEFFREY M · 2012 to 2017
$845k
NHLBI NIH HHS 1K23HL114868-01NHLBI NIH HHS 5T32HL007843-15NHLBI NIH HHS K23 HL114868NHLBI NIH HHS L30 HL115790NHLBI NIH HHS T32 HL007843NIDDK NIH HHS K24 DK090203NIDDK NIH HHS K24DK090203
6 · The paper itself

Abstract

objectivesThis study sought to determine if the timing of hemoconcentration influences associated survival.

backgroundIndicating a reduction in intravascular volume, hemoconcentration during the treatment of decompensated heart failure has been associated with reduced mortality. However, it is unclear if this survival advantage stems from the improved intravascular volume or if healthier patients are simply more responsive to diuretics. Rapid diuresis early in the hospitalization should similarly identify diuretic responsiveness, but hemoconcentration this early would not indicate euvolemia if extravascular fluid has not yet equilibrated.

methodsConsecutive admissions at a single center with a primary discharge diagnosis of heart failure were reviewed (N = 845). Hemoconcentration was defined as an increase in both hemoglobin and hematocrit levels, then further dichotomized into early or late hemoconcentration by using the midway point of the hospitalization.

resultsHemoconcentration occurred in 422 (49.9%) patients (41.5% early and 58.5% late). Patients with late versus early hemoconcentration had similar baseline characteristics, cumulative in-hospital loop diuretic administered, and worsening of renal function. However, patients with late hemoconcentration versus early hemoconcentration had higher average daily loop diuretic doses (p = 0.001), greater weight loss (p < 0.001), later transition to oral diuretics (p = 0.03), and shorter length of stay (p < 0.001). Late hemoconcentration conferred a significant survival advantage (hazard ratio: 0.74 [95% confidence interval: 0.59 to 0.93]; p = 0.009), whereas early hemoconcentration offered no significant mortality benefit (hazard ratio: 1.0 [95% confidence interval: 0.80 to 1.3]; p = 0.93) over no hemoconcentration.

conclusionsOnly hemoconcentration occurring late in the hospitalization was associated with improved survival. These results provide further support for the importance of achieving sustained decongestion during treatment of decompensated heart failure.

Indexed as

HematocritAcute DiseaseAgedCohort StudiesDiureticsFemaleGlomerular Filtration RateHeart FailureHemoglobinsHumansMaleMiddle AgedSurvivalTime FactorsDiureticsHemoglobinsacute decompensated heart failureADHFBNPB-type natriuretic peptideCIconfidence intervaldecompensated heart failureeGFRestimated glomerular filtration ratehazard ratioHCHcthematocrithemoconcentrationhemoglobinHgbHRinterquartile rangeIQRmortalityodds ratioORworsening renal functionWRF

Identifiers

PMID23747773
PMCPMC3892152

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.